Overview
I am a neuro-oncologist, neurologist, and palliative care physician at the Preston Robert Tisch Brain Tumor Center. I also provide neuro-oncology expertise for the National Tele-Oncology Program and National Precision Oncology Program at the Veteran's Health Administration. My clinical and research interests encompass supportive care and palliative care with a special interest in older adults with brain tumors. The incidence of malignant brain tumors like glioblastoma and non-malignant tumors like meningioma affect aging populations and it is crucial to be able to provide better care for these patients.
Current Appointments & Affiliations
Associate Professor of Neurosurgery
·
2025 - Present
Neurosurgery,
Neurosurgery
Associate Professor in Neurology
·
2025 - Present
Neurology, General & Community Neurology,
Neurology
Member of the Duke Cancer Institute
·
2018 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Data from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Other · December 17, 2025 <div>AbstractPurpose:<p>Glioblastoma (GBM) is the most common aggressive primary malignant brain tumor in adults with a median age of onset of 68 to 70 years old. Although advanced age is often associated with poorer GBM patient surviva ... Full text CiteSupplementary Data F1 from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Other · December 17, 2025 <p>Supplementary Figures</p> ... Full text CiteSupplementary Data T1 from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Other · December 17, 2025 <p>Supplementary Tables</p> ... Full text CiteRecent Grants
MOMENTUM-I: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF [177LU]LU-DOTA-TATE IN ADULTS WITH PROGRESSIVE INTRACRANIAL GRADE 1-3 MENINGIOMA
Clinical TrialPrincipal Investigator · Awarded by RTOG Foundation · 2025 - 2030ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Clinical TrialPrincipal Investigator · Awarded by Chimerix, Inc. · 2023 - 2028Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants with NF2 Mutated Meningiomas
Clinical TrialPrincipal Investigator · Awarded by Recursion Pharmaceuticals, Inc · 2022 - 2027View All Grants
Education, Training & Certifications
Tulane University, School of Medicine ·
2011
M.D.
The George Washington University ·
2006
M.P.H.
Northwestern University ·
2001
B.A.